Financial Survey: Xenetic Biosciences (NASDAQ:XBIO) and Ampio Pharmaceuticals (NYSE:AMPE)

Ampio Pharmaceuticals (NYSE:AMPE) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ampio Pharmaceuticals and Xenetic Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	0.00
Xenetic Biosciences	$2.50 million	1.43	-$4.14 million	($2.57)	-0.90

Xenetic Biosciences has higher revenue and earnings than Ampio Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ampio Pharmaceuticals and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Xenetic Biosciences	-161.63%	-49.51%	-43.99%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ampio Pharmaceuticals and Xenetic Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0	0	0	0	0.00
Xenetic Biosciences	0	1	0	0	2.00

Volatility & Risk

Ampio Pharmaceuticals has a beta of 3.77, suggesting that its stock price is 277% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Summary

Xenetic Biosciences beats Ampio Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.